

Rami Kahwash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4460/publications.pdf>

Version: 2024-02-01

28
papers

875
citations

933447

10
h-index

642732

23
g-index

28
all docs

28
docs citations

28
times ranked

1633
citing authors

#	ARTICLE	IF	CITATIONS
1	Will Complement Inhibition Be the New Target in Treating COVID-19â€™Related Systemic Thrombosis?. <i>Circulation</i> , 2020, 141, 1739-1741.	1.6	240
2	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]). <i>Circulation</i> , 2018, 137, 364-375.	1.6	206
3	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. <i>JACC: Heart Failure</i> , 2018, 6, 874-883.	4.1	159
4	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. <i>JAMA Cardiology</i> , 2018, 3, 968.	6.1	121
5	Optimizer Smart in the treatment of moderate-to-severe chronic heart failure. <i>Future Cardiology</i> , 2020, 16, 13-25.	1.2	16
6	Role of the Pulmonary Artery Catheter in Diagnosis and Management of Heart Failure. <i>Cardiology Clinics</i> , 2011, 29, 281-288.	2.2	15
7	Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education. <i>American Journal of Medicine</i> , 2018, 131, 974-978.	1.5	13
8	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1912-1917.	1.6	13
9	Recognition and Management of Sleep-Disordered Breathing in Chronic Heart Failure. <i>Current Heart Failure Reports</i> , 2011, 8, 72-79.	3.3	12
10	Cardiac contractility modulation in patients with advanced heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 635-645.	1.5	12
11	C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19. <i>Journal of Clinical Immunology</i> , 2021, 41, 729-732.	3.8	12
12	AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. <i>Cancer Medicine</i> , 2021, 10, 965-973.	2.8	12
13	Role of the Pulmonary Artery Catheter in Diagnosis and Management of Heart Failure. <i>Heart Failure Clinics</i> , 2009, 5, 241-248.	2.1	9
14	Evidence of aldosterone synthesis in human myocardium in acute myocarditis. <i>International Journal of Cardiology</i> , 2019, 275, 114-119.	1.7	6
15	AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 3778.	2.4	6
16	High-dose intravenous glucocorticoids are effective in the acute management of ventricular arrhythmias in cardiac sarcoidosis: A case series. <i>HeartRhythm Case Reports</i> , 2020, 6, 706-710.	0.4	6
17	A Practical Approach to the Identification and Management of Sleep-Disordered Breathing in Heart Failure Patients. <i>Sleep Medicine Clinics</i> , 2017, 12, 205-219.	2.6	4
18	Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.6	4

#	ARTICLE	IF	CITATIONS
19	The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis. <i>Blood</i> , 2019, 134, 1833-1833.	1.4	4
20	AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes. <i>Blood</i> , 2019, 134, 2029-2029.	1.4	2
21	A case report: pause and consider the late complications of heart transplantation. <i>European Heart Journal - Case Reports</i> , 2019, 3, ytz107.	0.6	1
22	AL Amyloidosis: The Prognostic Impact of Maintenance Therapy Following ASCT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S229-S230.	2.0	1
23	Cardiac Contractility Modulation in Heart Failure: Mechanisms and Clinical Evidence. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.9	1
24	Just Because You Can, Does That Mean You Should?. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 1130-1131.	1.7	0
25	Management of Sleep-Disordered Breathing in Heart Failure. <i>Current Sleep Medicine Reports</i> , 2018, 4, 202-209.	1.4	0
26	Targeted Therapeutics for Transthyretin amyloid cardiomyopathy: Time to Move Forward. <i>Journal of Cardiac Failure</i> , 2019, 25, S29.	1.7	0
27	Imaging Device Therapy. <i>Heart Failure Clinics</i> , 2019, 15, 305-320.	2.1	0
28	Clinical implications of atrial natriuretic peptide amyloidosis. <i>BMJ Case Reports</i> , 2021, 14, e242856.	0.5	0